Navigation Links
Low-Dose Steroid Combined With Lenalidomide Prolongs Survival,Compared With High-Dose Steroid for Multiple Myeloma Treatment

WASHINGTON, April 4, 2007-Preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma, a cancer typically found in bone marrow, has shown that the use of a low dose of the steroid dexamethasone (Decadron ®), in combination with lenalidomide (Revlimid ®) is associated with improved survival when compared to a treatment regimen with lenalidomide and a higher, standard dose of dexamethasone. The clinical trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG).

The data monitoring committee overseeing the trial (known as E4A03) recommended that the survival results from a recent interim analysis be made public because of early differences being seen in overall survival rates. Researchers found that patients in the study who received low-dose dexamethasone and lenalidomide had a one-year survival of 96 percent compared to 86 percent for patients treated with the standard-dose of dexamethasone and lenalidomide. In addition, there were fewer side effects associated with the low-dose dexamethasone and lenalidomide. Detailed results from this trial will be presented at the American Society of Clinical Oncology annual meeting in Chicago, Ill., from June 1 to 5, 2007.

These results have major implications for myeloma therapy, noted study chair Vincent Rajkumar, M.D., Mayo Clinic, Rochester, Minn. The results of this study, particularly lenalidomide plus low-dose dexamethasone, are very positive and in my opinion represent a real step forward in the treatment of this disease.

A total of 445 patients with newly diagnosed multiple myeloma, who had not previously received chemotherapy, were enrolled in this study between 2004 and 2006. Patients were randomized to one of two treatment arms. One patient group receive
'"/>




Page: 1 2 3

Related medicine technology :

1. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
2. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
3. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
4. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
5. Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer
6. Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients
7. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
8. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
9. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
10. Gentiums Defibrotide Seen as Active in Multiple Myeloma
11. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
Post Your Comments:
(Date:5/22/2012)... -- Health Diagnostic Laboratory, Inc. (HDL, Inc.), a CAP ... Lipid Association (NLA) with a non-restricted educational grant to ... cardiovascular health across the United States. In addition to ... the lead sponsors of the 2012 Annual Scientific Sessions ... 3, 2012. "Health Diagnostic Laboratory knows ...
(Date:5/22/2012)... May 22, 2012  Boehringer Ingelheim announced ... evaluating the investigational compound tiotropium delivered once-daily ... adolescents with symptomatic, moderate persistent asthma. The ... Meeting of the American Thoracic Society (ATS ... confirmatory Phase III trial program named UniTinA-asthma™ ...
(Date:5/22/2012)... /PRNewswire-iReach/ -- APEX BIOSTRATEGISTS, A FULL SERVICE ... THE RECENT ASSET SALE BY NPE SYSTEMS, INC. AND ... TO BECKMAN COULTER. NPE AND BLUE OCEAN WERE TECHNOLOGY ... DIAGNOSTIC BLOOD AND TISSUE TESTING FOR PATIENT MONITORING AND ... IN THE SALE OF FLOW CYTOMETRY SYSTEMS TO HOSPITALS ...
Breaking Medicine Technology:Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona 2Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 2Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 3Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 4Apex BioStrategists Advises On Flow Cytometry Sale To Coulter 2Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference 10431 1Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference 10431 2Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference 10431 3Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference 10431 4Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference 10431 5Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference 10431 6Fosun Pharma Acquires 2414 Million of Chindex Stock 10428 1Fosun Pharma Acquires 2414 Million of Chindex Stock 10428 2Fosun Pharma Acquires 2414 Million of Chindex Stock 10428 3Fosun Pharma Acquires 2414 Million of Chindex Stock 10428 4Fosun Pharma Acquires 2414 Million of Chindex Stock 10428 5Fosun Pharma Acquires 2414 Million of Chindex Stock 10428 6Fosun Pharma Acquires 2414 Million of Chindex Stock 10428 7Fosun Pharma Acquires 2414 Million of Chindex Stock 10428 8Fosun Pharma Acquires 2414 Million of Chindex Stock 10428 9A step toward a new sunscreen 3F 15110 1A step toward a new sunscreen 3F 15110 2A step toward a new sunscreen 3F 15110 3
... Age: Comparison by Interventional Radiologists Shows No Difference ... DIEGO, March 9 A new study shows ... it doesn,t matter if you,re young or old: ... maintaining access to one,s circulatory system to provide ...
... dosed every two weeks met the primary efficacy ... alfa-2a dosed weekly in patients with genotype 1 ... Albuferon had comparable rates of serious and/or severe ... global marketing applications planned in fall 2009 -ROCKVILLE, ...
Other Medicine Technology:For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold 2For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold 3For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold 4Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 2Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 3Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 4Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 5Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 7Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 8Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 9Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 10
(Date:5/23/2012)... In one of the most comprehensive analyses to ... prostate cancer, researchers at UPMC found that this now-dominant ... surgery, despite little scientific evidence of long-term improved patient ... and will appear in the July issue of the ... the first studies based on actual direct and indirect ...
(Date:5/23/2012)... connections as we age help keep us sharp in later ... found. , Older people with robust brain ,wiring, that ... can process information quickly and that this makes them ... findings, joining distant parts of the brain together with better ... in a single part of the brain. , However ...
(Date:5/23/2012)... use of physical restraints in nursing homes can ... more training and supportive materials for staff, residents ... Despite legal regulations and evidence that they ... and belts still are frequently used in nursing ... of physical-restraint use in U.S. nursing homes is ...
(Date:5/23/2012)... ROCHESTER, Minn. -- Mayo Clinic researchers will present ... other urological research at the annual meeting of ... Mayo Clinic urologists will also be available to ... , Mayo Clinic studies that will be presented ... negative impact on overall survival from post-prostate surgery ...
(Date:5/22/2012)... Storrs HealthDay Reporter , , TUESDAY, May 22 ... sleep apnea, a common cause of snoring and daytime ... hazard associated with the condition -- the risk of ... the number of new cases of high blood pressure ... positive airway pressure therapy, or CPAP, for either about ...
Breaking Medicine News(10 mins):Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 3Health News:Well-connected brains make you smarter in older age 2Health News:Study Offers Ways to Decrease Use of Restraints at Nursing Homes 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Health News:Sleep Apnea 'Mask' Might Also Help the Heart 2Health News:Sleep Apnea 'Mask' Might Also Help the Heart 3Health News:Sleep Apnea 'Mask' Might Also Help the Heart 4
... Allergies Send 50,000 Americans to the Emergency Room Annually , ... new study from the Mayo Clinic published in the December issue ... indicates a higher incidence of anaphylactic reactions than previously reported. ... "The etiology and incidence of anaphylaxis in Rochester, Minnesota," Wyatt W. ...
... December 11, 2008 The American Cancer Society ... Terry Awards for Exemplary Leadership in Tobacco Control. The ... General Luther L. Terry, M.D., who led the landmark ... lung cancer and other illnesses. Dr. Terry,s courageous and ...
... Research Group (MRG) analyst Deanna Vankessel, author of the recently published ... report, is available to offer extensive expertise on the recent FDA ... the knee. , , MRG,s ... , , , ...
... Expected to Begin in December - , , ... Wyeth Pharmaceuticals, a division of Wyeth (NYSE: ... trial of neratinib (HKI-272) in women with advanced HER-2-positive breast cancer. ... with advanced breast cancer positive for the ErbB-2 receptor (also known ...
... Female Health Company (NYSE Alternext: FHC) has announced that the ... Advisory Committee has unanimously voted that the company,s second-generation female ... condition. , , The ... the condition that the FC2 Female Condom,s instructions for use ...
... with ribavirin for previously untreated children with chronic hepatitis ... , KENILWORTH, N.J., Dec. 12 Schering-Plough ... the U.S. Food and Drug Administration (FDA) has granted ... USP) combination therapy for use in previously untreated patients ...
Other Medicine News:Health News:Incidence of Anaphylaxis Higher Than Previously Reported 2Health News:Incidence of Anaphylaxis Higher Than Previously Reported 3Health News:American Cancer Society recognizes international tobacco control leaders 2Health News:American Cancer Society recognizes international tobacco control leaders 3Health News:American Cancer Society recognizes international tobacco control leaders 4Health News:American Cancer Society recognizes international tobacco control leaders 5Health News:American Cancer Society recognizes international tobacco control leaders 6Health News:Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 3Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7
ArcticTemp Upright Freezer -20C. Quick, even freezing. Heavy duty compressor. Deep door racks. Front gated bottom shelf. Interior light. Locks One year warranty on unit and 5 year warranty on compres...
Digital Thermostat. , Exteriorbaked enamel-on-steel. , Interiorwhite anodized aluminum. , Electronic temperature control. , Temperature -20C , Positive seal doors. , Keyed door lock. , Interi...
... accurate portable, waterproof system for pH, mV (ORP), ... results can be obtained when used with a ... This GLP/GMP compliant system includes an RS-232 interface ... Up to 100 data sets can be stored ...
... portable system for pH, mV (ORP), relative mV ... be obtained when used with a temperature probe ... compliant system includes an RS-232 interface to connect ... 100 data sets can be stored for later ...
Medicine Products: